In Massachusetts, Xenetic Biosciences, Inc. has a new Chief Scientific Officer, Curtis A. Lockshin. Lockshin’s experience with research and development in the biopharmaceutical industry and his various biomaterials, therapeutics and biosensors inventions and patents will come in handy in his new role at Xenetic, a biopharmaceutical company. Lockshin was formerly a CEO, or served in other executive roles, at SciVac Therapuetics, VBI Vaccines, Guardum Pharmaceuticals, and OPKO Health. Lockshin will help Xenetic with their focus on next-gen biologic drugs and oncology therapeutics. Scott Maguire, Chief Executive Officer of Xenetic said in their press release “With our second important executive level appointment since our Nasdaq listing, Xenetic now has a structure to deliver on what we believe will be a transformational 2017.”
Latest article
Data boom to data shroom: Mycelium could one day be data storage
In Ohio, scientists at Ohio State University have shown that mushroom mycelium can act as a form of data storage. In controlled lab experiments,...
Wooden compass points dementia patients back home
In the Netherlands, a startup has unveiled a device for dementia patients that is comprised of a single arrow that points to only one...
Snack to the future: Nutri3D wants to 3D print your next sweet treat
In Italy, researchers in the Nutri3D project have unveiled prototypes of nutrient-rich sweet snacks made from cultured plant cells, fruit byproducts, and 3D printing....